Genentech Announces FDA Approval of Xofluza (baloxavir marboxil) for People at High Risk of Developing Influenza-Related Complications

FDA News, New FDA Approvals
October 17, 2019
A+ A-
Email Print

Article Link: Genentech Announces FDA Approval of Xofluza (baloxavir marboxil) for People at High Risk of Developing Influenza-Related Complications

South San Francisco, CA — October 17, 2019 — Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil)…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post